Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome

Thrombosis and Haemostasis

Volumn 80, Issue 3, 1998, Pages 495-498

  Van Genderen, Perry J J ^a   Boertjes, Ria C ^b   Van Mourik, Jan A ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; IMMUNOGLOBULIN; PEPTIDE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR PROPEPTIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; VON WILLEBRAND DISEASE;

EID: 0031725673     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615235     Document Type: Article

References (15)

1. Fay PJ, Kawai Y, Wagner DD, Ginsburg D, Bonthron D, Ohlsson-Wilhelm BM, Chavin SI, Abraham GN, Handin RI, Orkin SH, Montgomery RR, Marder VJ. Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II. Science 1986; 232: 995.
2. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad USA 1987; 84: 1955-9.
3. Borchiellini A, Fijnvandraat K, ten Gate JW, Pajkrt D, van Deventer SJH, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-d-arginine vasopressin in humans. Blood 1996; 88: 2951-8.
4. McCarroll DR, Ruggeri ZM, Montgomery RR. Correlation between circulating levels of von Willebrand's antigen II and von Willebrand factor: discrimination between type 1 and type II von Willebrand's disease. J Lab Clin Med 1984; 103: 704-11.
5. van Genderen PJJ, Vink T, Michiels JJ, van 't Veer MB, Sixma JJ, van Vliet HHDM. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994; 84: 3378-84.
6. van Genderen PJJ, Michiels JJ, van der Poel - van de Luytgaarde SCPAM, van Vliet HHDM. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary lhrombocythemia: relationship with platelet count. Ann Hematol 1994; 69: 81-4.
7. Budde U, van Genderen PJJ. Acquired von Willebrand disease in patients with high platelet counts. Sem Thromb Hemost 1997; 23: 425-31.
8. Hakkert BC, Rentenaar JM, van Mourik JA. Monocytes enhance endothelial von Willebrand factor release and prostacyclin production with different kinetics and dependency on intercellular contact between these two cell types. Br J Haematol 1992; 80: 495.
9. Stel HV, Sakariassen KS, Scholte BJ, Veerman ECI, van der Kwast TH, de Groot PG, Sixma JJ, van Mourik JA. Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation adn platelet adherence to subendothelium. Blood 1984; 63: 1408.
10. Fay PJ. Factor VIII structure and function. Thromb Haemost 1993; 70: 63.
11. Scott JP, Vokac EA, Schroeder T, et al. The von Willebrand factor propolypeptide, von Willebrand factor antigen II, distinguishes von Willebrand syndrome (AvWS) due to the decreased synthesis of vWF from AvWS due to increased clearance of vWF [abstract]. Blood 1995; 86: 196a.
12. McCarroll DR, Ruggeri ZM, Montgomery RR. The effect of DDAVP on plasma levels of von Willebrand antigen II in normal individuals and patients with von Willebrand's disease. Blood 1984; 63: 532-5.
13. van Genderen PJJ, Leenknegt H, Budde U, Michiels JJ. Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 1996; 22 (Suppl.1): 79-82.
14. van Genderen PJJ, Papatsonis DNM, Michiels JJ, Wielenga JJ, Stibbe J, Huikeshoven FJM. High-dose intravenous gammaglobulin therapy for acquired von Willebrand disease. Postgrad Med J 1994; 70: 916-20.
15. van Genderen PJJ, Terpstra W, Michiels JJ, Kapteijn L, van Vliet HHDM. High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease. Thromb Haemost 1995; 73: 890-1.